Search results

761 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
Research recommendations Remove Research recommendations filter
In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
Clinical guidelines Remove Clinical guidelines filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Diagnostics guidance Remove Diagnostics guidance filter
Social care guidelines Remove Social care guidelines filter

Extracorporeal whole liver perfusion for acute liver failure

In development [GID-IPG10164] Expected publication date: 31 March 2021

Type

Interventional procedures guidance

Status

In development
Electrohydraulic lithotripsy for difficult-to-treat bile duct stones

In development [GID-IPG10151] Expected publication date: 28 April 2021

Type

Interventional procedures guidance

Status

In development
Permanent His-bundle pacemaker implantation for heart failure

In development [GID-IPG10145] Expected publication date: 28 April 2021

Type

Interventional procedures guidance

Status

In development
Deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults

In development [GID-IPG10143] Expected publication date: 28 April 2021

Type

Interventional procedures guidance

Status

In development
Transvenous obliteration of varices

In development [GID-IPG10206] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Image-guided cryoablation of peripheral neuroma for chronic pain

In development [GID-IPG10208] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease

In development [GID-IPG10209] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
High tibial osteotomy with adjustable magnetic nail insertion for symptomatic medial knee osteoarthritis

In development [GID-IPG10142] Expected publication date: 24 February 2021

Type

Interventional procedures guidance

Status

In development
Pharyngeal Electrical Stimulation for neurogenic dysphagia

In development [GID-IPG10212] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Trabeculectomy with biodegradable collagen matrix implant for glaucoma

In development [GID-IPG10211] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver

In development [GID-IPG10177] Expected publication date: 21 April 2021

Type

Interventional procedures guidance

Status

In development
Transvaginal laser therapy for urogenital atrophy

In development [GID-IPG10155] Expected publication date: 26 May 2021

Type

Interventional procedures guidance

Status

In development
Transvaginal laser therapy for stress urinary incontinence

In development [GID-IPG10156] Expected publication date: 26 May 2021

Type

Interventional procedures guidance

Status

In development
Laser lithotripsy for difficult-to-treat bile duct stones

In development [GID-IPG10157] Expected publication date: 26 May 2021

Type

Interventional procedures guidance

Status

In development
Ex-situ machine perfusion for extracorporeal preservation of lungs (ex - vivo lung perfusion) for transplantation

In development [GID-IPG10149] Expected publication date: 26 May 2021

Type

Interventional procedures guidance

Status

In development
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]

In development [GID-TA10582] Expected publication date: 19 May 2021

Type

Technology appraisal guidance

Status

In development
Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

In development [GID-TA10457] Expected publication date: 19 May 2021

Type

Technology appraisal guidance

Status

In development
Pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer [ID1500]

In development [GID-TA10399] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Selumetinib for treating differentiated thyroid cancer ID1079

In development [GID-TA10207] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]

In development [GID-TA10249] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
NY-ESO-1 T-cells for treating synovial sarcoma ID1286

In development [GID-TA10205] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]

In development [GID-TA10251] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297

In development [GID-TA10311] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ovarian, fallopian tube and peritoneal cancer - rucaparib [ID1184]

In development [GID-TA10168] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Enzalutamide for the treatment of hormone refractory prostate cancer TA316

In development [GID-TA10267] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
ATA129 for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus ID1203

In development [GID-TA10204] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Carotuximab with pazopanib for treating advanced angiosarcoma ID1503

In development [GID-TA10401] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Asunercept for treating glioblastoma [1301]

In development [GID-TA10227] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]

In development [GID-TA10225] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Durvalumab (Imfinzi) + Tremelimumab + standard chemotherapy for non-small cell lung cancer (NSCLC) lacking activating EGFR mutations and ALK fusions ID1538

In development [GID-TA10422] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Furosemide micro-pump for treating oedema associated with heart failure (ID1061)

In development [GID-TA10179] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Daratumumab in combination for untreated multiple myeloma when stem cell transplant is unsuitable ID1492

In development [GID-TA10441] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

In development [GID-TA10446] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093]

In development [GID-TA10445] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable [ID1510]

In development [GID-TA10449] Expected publication date: 19 April 2021

Type

Technology appraisal guidance

Status

In development
Short bowel syndrome - teduglutide [ID885]

In development [GID-TA10048] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Omalizumab for treating chronic rhinosinusitis with nasal polyps [ID1650]

In development [GID-TA10558] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Enzalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer ID1605

In development [GID-TA10488] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

In development [GID-TAG363] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nitisinone for treating alkaptonuria [ID2691]

In development [GID-TA10659] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency ID1498

In development [GID-TA10420] Expected publication date: 23 June 2021

Type

Technology appraisal guidance

Status

In development
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]

In development [GID-TA10024] Expected publication date: 28 June 2017

Type

Technology appraisal guidance

Status

In development
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]

In development [GID-TA10046] Expected publication date: 22 November 2017

Type

Technology appraisal guidance

Status

In development
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

In development [GID-TA10664] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]

In development [GID-TA10611] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for previously treated endometrial cancer [ID1205]

In development [GID-TA10243] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289

In development [GID-TA10210] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401

In development [GID-TA10326] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]

In development [GID-TA10405] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]

In development [GID-TA10252] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development